NEWS DETAIL

KRYSTAL-10 在 ESMO GI 2026 發表：Adagrasib 合併西妥昔單抗對比化療治療 KRAS G12C 突變型轉移性結直腸癌 – Oncodaily

KRYSTAL-10 at ESMO GI 2026: Adagrasib Plus Cetuximab vs Chemotherapy in KRAS G12C-Mutated mCRC O…

醫藥資訊 July 8, 2026

正文內容

KRYSTAL-10 at ESMO GI 2026: Adagrasib Plus Cetuximab vs Chemotherapy in KRAS G12C-Mutated mCRC / adagrasib plus cetuximab, cancer, cancer care, Cancer, adagrasib plus cetuximab, cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical trials, colorectal cancer, ESMO, ESMO GI 2026, ESMO GI Cancers Congress 2026, ESMO-GI, KRASG12C inhibitors, KRYSTAL-10, OncoDaily, Oncology

文章相關商品

系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。

常見問題

Which products are related to this article?

The system matched these relevant products from the article content: 阿達格拉西布片 ADADX Adagrasib、盧修斯阿達格拉西布 Adagrasib 在線購買.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

KRYSTAL-10 在 ESMO GI 2026 發表：Adagrasib 合併西妥昔單抗對比化療治療 KRAS G12C 突變型轉移性結直腸癌 – Oncodaily

正文內容

文章相關商品

阿達格拉西布片 ADADX Adagrasib

盧修斯 阿達格拉西布 Adagrasib 在線購買

常見問題

盧修斯阿達格拉西布 Adagrasib 在線購買